Stocks and Investing
Stocks and Investing
Thu, July 6, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Roy Buchanan Reiterated (ABUS) at Buy and Held Target at $6 on, Jul 6th, 2023
Roy Buchanan of JMP Securities, Reiterated "Arbutus Biopharma Corporation" (ABUS) at Buy and Held Target at $6 on, Jul 6th, 2023.
Roy has made no other calls on ABUS in the last 4 months.
There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Roy's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Roy
- Ed Arce of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $6 on, Thursday, June 22nd, 2023
- Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $6 on, Thursday, June 22nd, 2023
Contributing Sources